Radio and PodcastRadio and PodcastLive Radio & Podcasts
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns artwork
Science & Medicine

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Jul 7, 20222:00Science & Medicine

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lym...

About This Episode

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Listen to an audio podca...

Podcast

This episode belongs to FDA Drug Safety Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jul 7, 2022, 2:00 long, audio available.

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.

Questions About This Episode

What is FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns about?

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL)

Where can I listen to FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns?

You can listen to FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns from?

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

How long is this episode?

This episode is 2:00 long.

When was this episode published?

This episode was published on Jul 7, 2022.

Can I save FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from FDA Drug Safety Podcasts?

Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns?

You can listen to FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.

What are the episode details?

Published Jul 7, 2022 and 2:00 long